World Health Organization & Gilead Sciences

World Health Organization: The World Health Organization recommended prioritizing three experimental treatments and several vaccine candidates for the Bundibugyo strain of Ebola, and is working with authorities to design and implement clinical trials.

Gilead Sciences: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.

World Health Organization: The World Health Organization has declared the Ebola outbreak a public health emergency of international concern, providing funds, dispatching teams, and coordinating global response efforts while expressing deep concern over the outbreak's scale and speed.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

World Health Organization: Leading the international response, coordinating clinical trials, and issuing warnings; faces criticism over response speed.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

World Health Organization: Leading the international response, warning of undercount and funding gaps; launched the EBO-PEP trial.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

World Health Organization: The World Health Organization is leading the international response to the Ebola outbreak in the Democratic Republic of the Congo, revising its risk assessment to 'very high' nationally and launching a $518 million plan to combat the spread. Its efforts are hampered by conflict and community mistrust.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

World Health Organization: WHO Director-General Tedros warned that progress is fragile without sustained funding, supporting the report's message.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak in the Democratic Republic of the Congo>>> and Uganda>>> a public health emergency of international concern, highlighting the severity and rapid spread of the virus.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.

World Health Organization: WHO is referenced regarding pandemic origins, but it is not directly involved in the contempt vote. Its role is background.

Gilead Sciences: Gilead is mentioned in relation to Remdesivir, but it is not directly involved in the event. Its role is peripheral.